NRx Pharmaceuticals, Inc.
NRXP
$3.37
-$0.10-2.88%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.39M | 2.29M | 1.23M | 242.00K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.39M | 2.29M | 1.23M | 242.00K | -- |
| Cost of Revenue | 1.81M | 1.14M | 505.00K | 97.00K | -- |
| Gross Profit | 1.58M | 1.16M | 720.00K | 145.00K | -- |
| SG&A Expenses | 15.94M | 13.93M | 13.06M | 11.09M | 10.69M |
| Depreciation & Amortization | 197.00K | 131.00K | 68.00K | 27.00K | 3.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.36M | 19.48M | 17.41M | 15.47M | 14.13M |
| Operating Income | -19.96M | -17.19M | -16.19M | -15.23M | -14.13M |
| Income Before Tax | -23.48M | -24.54M | -28.62M | -38.06M | -33.79M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.48 | -24.54 | -28.62 | -38.06 | -33.79 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.48M | -24.54M | -28.62M | -38.06M | -33.79M |
| EBIT | -19.96M | -17.19M | -16.19M | -15.23M | -14.13M |
| EBITDA | -19.78M | -17.07M | -16.14M | -15.22M | -14.13M |
| EPS Basic | -0.74 | -1.28 | -1.57 | -2.32 | -2.21 |
| Normalized Basic EPS | -0.51 | -0.65 | -0.79 | -1.05 | -1.10 |
| EPS Diluted | -0.74 | -1.28 | -1.57 | -2.32 | -2.21 |
| Normalized Diluted EPS | -0.51 | -0.65 | -0.79 | -1.05 | -1.10 |
| Average Basic Shares Outstanding | 121.17M | 101.45M | 85.54M | 68.83M | 57.57M |
| Average Diluted Shares Outstanding | 121.17M | 101.45M | 85.54M | 68.83M | 57.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |